大洋生物(003017) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥176,677,783.46, representing a 29.91% increase compared to ¥136,004,982.75 in the same period last year[7]. - The net profit attributable to shareholders for Q1 2021 was ¥25,212,102.44, up 20.75% from ¥20,880,078.78 in the previous year[7]. - The basic earnings per share decreased by 8.70% to ¥0.42 from ¥0.46 in the previous year[7]. - Total operating income for Q1 2021 was CNY 185,348,041.63, compared to CNY 140,299,436.84 in the previous period, representing an increase of approximately 32.1%[47]. - Net profit for Q1 2021 reached CNY 25,212,102.44, up from CNY 20,880,078.78 in the same period last year, reflecting a growth of about 20.5%[44]. - Operating profit for Q1 2021 was CNY 29,065,427.47, compared to CNY 23,959,491.68 in the previous year, indicating an increase of approximately 21.5%[44]. - The company reported a total comprehensive income of CNY 25,212,102.44 for Q1 2021, compared to CNY 20,880,078.78 in the previous year, marking an increase of about 20.5%[45]. Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to ¥2,883,434.02, a 329.24% increase from a negative cash flow of ¥1,257,822.50 in the same period last year[7]. - Cash received from sales of goods and services was ¥122,331,178.17, reflecting a 57.98% increase from the previous year, indicating improved cash flow from sales[16]. - Cash paid for purchasing goods and services increased by 68.57% to ¥83,038,059.22, reflecting a larger procurement scale[16]. - Operating cash inflow totaled CNY 130,982,483.46, an increase from CNY 87,682,880.52 in the previous year[52]. - The company reported a net cash flow from operating activities of negative CNY 4,052,570.75, compared to negative CNY 1,312,184.27 last year[54]. - Cash and cash equivalents decreased to CNY 43,832,771.31, down from CNY 30,832,250.16 year-over-year[53]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,261,029,090.98, reflecting a 2.62% increase from ¥1,228,800,981.37 at the end of the previous year[7]. - The total liabilities increased to CNY 277,566,952.41 from CNY 270,670,723.57, reflecting a growth in financial obligations[36]. - The total current assets were CNY 616,941,084.51, with cash and cash equivalents of CNY 43,179,987.60[63]. - The company reported a total of CNY 464,188,199.89 in non-current assets, including fixed assets of CNY 230,777,114.28[63]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,112[11]. - The top shareholder, Chen Yanggui, holds 8.86% of the shares, amounting to 5,317,261 shares[11]. - The company did not engage in any repurchase transactions among the top ten shareholders during the reporting period[12]. Operating Costs and Expenses - Operating costs rose to ¥138,401,677.11, a 38.35% increase from ¥100,040,094.98, primarily due to increased sales volume and rising raw material prices[16]. - Management expenses increased by 37.23% to ¥12,124,838.45, attributed to higher employee wages and the cessation of pandemic-related social security exemptions[16]. - Financial expenses surged by 1278.82% to ¥617,971.53, mainly due to the capitalization of interest expenses ceasing as construction projects were completed[16]. - Total operating costs for Q1 2021 were CNY 157,953,163.19, up from CNY 115,595,032.17 in the previous year, representing an increase of approximately 36.6%[44]. Investment and Other Income - Non-recurring gains and losses totaled ¥5,068,628.26 for the reporting period, with government subsidies contributing ¥3,176,738.55[8]. - Other income increased by 61.77% to ¥7,660,946.85, largely from government subsidies related to the company's successful IPO[16]. - Investment income rose significantly by 1146.77% to ¥939,976.79, due to an increase in structured deposits[16]. - The company recorded investment income of CNY 939,976.79 in Q1 2021, compared to CNY 75,392.92 in the previous year, showing a significant increase[44]. Changes in Accounting and Financial Management - The company has established a financial derivatives trading management system to mitigate risks associated with currency fluctuations[22]. - The company has not reported any significant changes in its accounting policies for derivatives compared to the previous reporting period[22].